PARTNERS clinical trial begins enrolment for Bundibugyo virus disease treatments in the Democratic Republic of the Congo (who.int)

• PARTNERS trial opened enrolment on 2 July 2026 in the Democratic Republic of the Congo for Bundibugyo virus disease (BVD) patients.
• Evaluates MBP134 monoclonal antibody and remdesivir, alone or combined, for improving survival.
• Over 1,400 BVD cases, 210 recoveries, 440 deaths reported in DRC; no approved treatments exist.
• Platform trial allows future additions; integrated with response by MSF and ALIMA.

"The PARTNERS platform trial, sponsored by WHO and coordinated by INRB, ITM Belgium, and Oxford, has started enrolling patients in the DRC to evaluate MBP134 (monoclonal antibody) and remdesivir as treatments for Bundibugyo virus disease (BVD). As of the article, over 1,400 BVD cases, 210 recoveries, and 440 deaths have been reported in the DRC. No approved treatments exist for BVD. The trial integrates with outbreak response, with support from ALIMA and MSF, and includes an independent data safety monitoring board."